Who Is Ed Gein? Inside The Real-Life Story Of The 'Monster' Whose Grisly Crimes Inspired 'Psycho'

In a recent development, the CEO of MeiraGTx, a biotechnology company based in Alexandria, has sold shares worth $398,000. This transaction is noteworthy as it reflects the CEO's financial decisions and could influence investor sentiment regarding the company's future. Such sales can often raise questions about the company's performance and the CEO's confidence in its prospects.

Fans of the 'Monster' anthology series can rejoice as the release of 'Monster: The Ed Gein Story' starring Charlie Hunnam has sparked excitement about a potential fourth season. With the show's unique storytelling and captivating performances, viewers are eager to see what Netflix will bring next. The anticipation surrounding the series highlights its popularity and the audience's desire for more thrilling narratives.

Economist Clifford Winston has criticized President Trump's new $100,000 application fee for the H-1B visa program, calling it anti-innovation. This fee could deter skilled workers from coming to the U.S., which is crucial for maintaining the country's competitive edge in technology and innovation. Winston's comments highlight the potential negative impact on the economy and the tech industry, emphasizing the need for policies that encourage talent rather than restrict it.

Netflix's latest release, 'Monster: The Ed Gein Story,' has made headlines for all the wrong reasons, setting a record on Rotten Tomatoes for the lowest-rated serial killer show. This unfortunate milestone highlights the challenges Netflix faces in maintaining quality content, especially in a genre that has captivated audiences. The negative reception could impact viewer trust and future projects, making it a significant moment for the streaming giant.

Netflix's 'Monster: The Ed Gein Story' wraps up with a surprising twist that links Ed Gein to infamous serial killers like Ted Bundy. This finale not only captivates viewers with its shocking connections but also sparks discussions about the psychological profiles of these criminals, making it a significant addition to the true crime genre.

Mizuho has lowered its stock price target for Shift4 Payments due to international headwinds affecting the company's performance. This adjustment reflects concerns about the challenges Shift4 may face in global markets, which could impact its growth and profitability. Investors should pay attention to these developments as they could influence the stock's future trajectory.

RBC Capital has raised its price target for Select Medical's stock to $20, citing recent regulatory relief as a key factor. This adjustment reflects growing confidence in the company's future performance and highlights the positive impact of regulatory changes on its operations. Investors may see this as a promising sign for Select Medical's growth potential.

Mizuho has lowered its price target for Corteva's stock to $78 following the company's announcement of a stock split. This adjustment reflects concerns about the potential impact of the split on investor confidence and market performance. Investors should pay attention to how this change might affect Corteva's stock in the coming months, as it could influence trading strategies and overall market sentiment.

Zenas Biopharma has successfully licensed three promising autoimmune candidates from InnoCare, marking a significant step forward in their development pipeline. This collaboration not only enhances Zenas's portfolio but also underscores the growing importance of innovative treatments in the autoimmune space. The partnership is expected to accelerate research and bring new therapies to patients in need, highlighting the potential for improved health outcomes.

Frontline stock has received a reaffirmed 'Buy' rating from BTIG, reflecting confidence in the company's performance amid a robust tanker market. This endorsement is significant as it highlights the potential for growth and profitability in the shipping sector, which is currently benefiting from increased demand and favorable market conditions.

In a remarkable achievement, Yoshio Kitagawa, David Robson, and Omar Yaghi have been awarded the 2025 Nobel Prize in Chemistry for their groundbreaking work in the field of porous materials. This recognition not only highlights their innovative contributions but also underscores the importance of chemistry in addressing global challenges such as energy storage and environmental sustainability. Their research paves the way for future advancements that could significantly impact various industries and improve our daily lives.